It is being tested as a monotherapy in phase 2 clinical trials for RA (NCT04991753) and SLE (NCT04882878), and in combination with the anti-TNF drug certolizumab for RA (NCT06028438). The gene discussed is TNF; the disease is rheumatoid arthritis.